Sold as Synkayvite, Kappadione. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Menadiol Sodium Diphosphate (sold as Synkayvite, Kappadione), first approved Jul 15, 1941, with 0 new uses approved and 0 published complete response letters.
| Jul 15, 1941 | SynkayviteNDA 3718 | Roche | 3 | Discontinued |
| — | KappadioneNDA 5725 | Lilly | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA